PPD Sees Biomarkers As Key To Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking to accelerate its acquisition of SurroMed's biomarker discovery services business, with the goal of closing a deal in the first quarter of 2005. FDA has placed biomarker development "near the top" of its "Critical Path" initiative, PPD CEO Eshelman notes.